ADCY2, AGAP3, AGK, ALK, BRAF, BRAF/RAS/NF1-mutant tumors, CANT1, CCDC6, CCT8, CDH3, CDKN2A, DIP2B, EFNB1, EML4, ETV4, Fusion positive melanomas, GNB1, LRCH3, MAP4, MAST2, MEK, MLPH, NAGS, NF1, NOTCH1, RAF1, RAS, RET, RUFY1, TERT, TERT promoter, TERT promoter mutations, gene fusions, malignancies, melanoma, melanomas, patient, patients, prostate cancer, thyroid cancer, trametinib, triple wild, triple wild-type melanomas, tumors, wild-, wild-type melanomas